Lonza– tag –
-
Lonza Expands US Manufacturing with New Spray Drying Facility; Samsung Biologics Secures $262M European CDMO Deal
Endpoints News Switzerland, South Korea, USA Overview Lonza announced a significant expansion of its U.S. manufacturing capabilities with a new commercial spray drying facility in Bend, Oregon, projected for completion by 2029 and creati... -
Lonza, Sartorius, and FUJIFILM Diosynth Bolster Biopharmaceutical Manufacturing Capacity, Highlighting Single-Use Technology as Key
SNS Insider Unknown Overview This article highlights the biopharmaceutical manufacturing capacity expansions by Lonza Group, Sartorius, and FUJIFILM Diosynth Biotechnologies, as noted in the "Biopharmaceutical Fermentation Market" report... -
Lonza to Build Large-Scale Commercial Spray-Drying Facility in Bend, Oregon, Enhancing US Drug Manufacturing Capacity by 2029
24/7 BIOPHARMA USA Overview Lonza, a leading CDMO, has announced plans for a large-scale commercial spray-drying facility in Bend, Oregon. This investment solidifies Lonza's position as a premier CDMO provider for commercial-scale spray-... -
Lonza to Build New Spray-Drying Facility in Oregon, US, Bolstering CDMO Capabilities in Particle Engineering for Enhanced Bioavailability
SWI swissinfo.ch Switzerland Overview Lonza, a leading Swiss CDMO, announced on September 10, 2026, plans to construct a new state-of-the-art manufacturing facility in Bend, Oregon, specialized in spray-drying technology. Expected to be ... -
US Trade Policy and BIOSECURE Act Drive Major Reshaping and Investment in Global ADC Manufacturing Landscape
Bioprocess Online USA Overview U.S. trade policy and the BIOSECURE Act are significantly reshaping the Antibody-Drug Conjugate (ADC) manufacturing landscape, spurring substantial investments in capacity across the U.S., Europe, and Asia.... -
RayzeBio to Invest $173 Million in Radiopharmaceutical Manufacturing Plant to Accelerate Production Expansion
Fierce Biotech USA Overview RayzeBio announced plans to invest $173 million in the construction of a new radiopharmaceutical manufacturing plant, significantly expanding its production capacity. This substantial investment aims to meet t... -
Lonza Appoints Samanta Cimitan as Chief Commercial Officer (CCO) to Enhance Customer Engagement and Accelerate Growth
Fierce Pharma Switzerland Overview Lonza announced the appointment of Samanta Cimitan as its new Chief Commercial Officer (CCO), effective January 1, 2027. This strategic move aims to integrate Lonza's strategic enterprise account manage... -
Lonza and Entropic Unveil Scalable 96-Well 3D Human Skin Organoid Platform for Accelerated Screening
Scientist.com Switzerland Overview Lonza and Entropic have jointly developed a scalable 96-well 3D human skin organoid model, dramatically improving the efficiency of skin barrier function and injury screening. Utilizing Entropic's ZYRAL... -
Lonza Unveils Rapid Custom Media Prototyping Service (RaMP) to Drastically Accelerate Early Bioprocess Development Timelines
Outsourced Pharma Global Overview Lonza has launched its Rapid Media Prototyping Service (RaMP) to significantly shorten early bioprocess development timelines for biopharmaceutical companies. This service provides custom liquid and powd... -
Lonza Launches ‘RaMP’ Service, Accelerating Custom Media Supply to 10 Business Days for Early Bioprocess Development
Manufacturing Chemist Switzerland Overview Lonza has launched its Rapid Custom Media Prototyping (RaMP) service to significantly accelerate early bioprocess development. This new offering allows biopharmaceutical companies to receive cus...
